Elranatamab Demonstrates Sustained Efficacy with Reduced Dosing Frequency in Refractory Multiple Myeloma

The findings from the MagnetisMM-3 trial, a phase 2 study investigating elranatamab in refractory multiple myeloma, show a 61% overall response rate and demonstrate that patients transitioning from weekly or biweekly dosing to a four-week dosing schedule maintain durable responses and experience fewer adverse events. At ASH 2024, Dr. Alex Lesokhin discussed the extended follow-up study, which confirms elranatamab’s efficacy and safety profile, offering a new option for long-term management of multiple myeloma.